Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

H2 antagonist Rx-to-OTC switch saves $500,000 in managed care setting.

This article was originally published in The Tan Sheet

Executive Summary

H2 ANTAGONIST Rx-TO-OTC SWITCH IN MCO SETTING SAVES $500,000 in half a year, Diversified Pharmaceutical Services Regional Director of Clinical Programs Scott Enos reported at the American Managed Care Pharmacy annual meeting in Philadelphia May 1-2. The DPS program, which mandated the use of OTC H2s in place of low-dose, but not high-dose, Rx acid blockers for ulcer treatment in a managed care organization, "demonstrated a 50% decrease in per member per month (PMPM) cost and a 10% decrease in utilization" of the H2 antagonist, according to Enos. The decreases resulted in an "estimated savings of over $500,000 in the first five months."
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088417

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel